点击次数：

论文类型： 期刊论文

发表时间： 2022-06-30

发表刊物： Chinese Journal of Cell Biology

卷号： 41

期号： 12

页面范围： 2393-2405

ISSN号： 1674-7666

关键字： "acute myeloid leukemia; immunotherapy; targeted therapy"

CN号： 31-2035/Q

摘要： AML(acute myeloid leukemia)is an invasive hematological malignancy caused by the accumulation of immature leukemia cells in the blood and bone marrow.It's core treatment, induction of remission with high-dose conventional chemotherapy, followed by CR(complete remission)to achieve intensive and maintenance therapy, but the survival rate and the prognosis of the disease is still not ideal.For patients who are not suitable for intensive treatment and patients with relapsed or refractory diseases, there is an urgent need for alternative immunotherapy strategies.The progress in immunotherapy have revolutionized the cancer treatment in the past few years.New immunotherapeutics are entering the mainstream of oncology, providing new weapons for the prognosis and survival of AML, and increasingly showing its advantages for traditional treatment in the treatment of AML.Currently, there are five main immunotherapy regimens: HSC(hematopoietic stem cell), CAR-T(chimeric antigen receptor T-cell), monoclonal antibody drugs, NK(natural killer cell), DC(dendritic cell)vaccine.This paper will review the current research progress of AML immunotherapy and related molecular mechanism.

备注： 新增回溯数据